Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
| Title | Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. |
| Publication Type | Journal Article |
| Year of Publication | 2014 |
| Authors | Okamoto, A, Glasspool, RM, Mabuchi, S, Matsumura, N, Nomura, H, Itamochi, H, Takano, M, Takano, T, Susumu, N, Aoki, D, Konishi, I, Covens, A, Ledermann, JA, Mezzanzanica, D, Mezzazanica, D, Steer, C, Millan, D, McNeish, IA, Pfisterer, J, Kang, S, Gladieff, L, Bryce, J, Oza, AM |
| Journal | Int J Gynecol Cancer |
| Volume | 24 |
| Issue | 9 Suppl 3 |
| Pagination | S20-5 |
| Date Published | 11/2014 |
| ISSN | 1525-1438 |
| Keywords | Adenocarcinoma, Clear Cell, Combined Modality Therapy, Consensus, Female, Humans, Medical Oncology, Ovarian Neoplasms, Practice Guidelines as Topic, Societies, Medical |
| Abstract | Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration. |
| DOI | 10.1097/IGC.0000000000000289 |
| Alternate Journal | Int. J. Gynecol. Cancer |
| PubMed ID | 25341576 |
- Log in to post comments
- Google Scholar
- PubMed
- DOI